Dapolsertib hydrochloride

N/A

Report date: 2025/05/07 14:45:45
NMEFirst In Class

Base Information

Drug NameDapolsertib hydrochloride
Drug Alias NameSEL24SEL-24SEL-24-B489SEL-24-1MEN-1703 +[6] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionProto-oncogene serine/threonine-protein kinase Pim-1 inhibitorsTyrosine-protein kinase receptor FLT3 inhibitors
TargetsProto-oncogene serine/threonine-protein kinase Pim-1Tyrosine-protein kinase receptor FLT3
Therapy Area/IndicationsLymphoma, B-CellLeukemia, Myeloid, Acute
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesPolandItaly +[6] 
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesRyvu Therapeutics Sa
China Registration ClassN/A

Develop Information

Active CompaniesRyvu Therapeutics SaMenarini Group
Inactive CompaniesN/A
Active IndicationsLymphoma, B-CellLeukemia, Myeloid, Acute
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A